Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MC4R | P32245 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1854513 | 0.71 | SIGMAR1 (0.52) | SIGMAR1POLBMC4RHRH1HPGD | |
| SCHEMBL28563678 | 0.68 | HSP90AA1 (0.43) | NPC1RAB9AMEN1KMT2A | |
| SCHEMBL16226109 | 0.68 | OPRM1 (0.51) | MC4RHRH1CHRM1MAPK1SMN1; SMN2 | |
| SCHEMBL16268555 | 0.64 | HSP90AA1 (0.41) | NPC1RAB9A | |
| SCHEMBL7503020 | 0.62 | CHRNB2 (0.33) | SIGMAR1ALDH1A1 | |
| SCHEMBL10681519 | 0.62 | ATM (0.46) | — | |
| SCHEMBL2465377 | 0.62 | CYP1A2 (0.38) | SIGMAR1HPGDMEN1KMT2A | |
| SCHEMBL13041010 | 0.61 | SIGMAR1 (0.58) | SIGMAR1POLBMC4RHRH1HTR6 | |
| SCHEMBL31547211 | 0.61 | SIGMAR1 (0.58) | SIGMAR1POLBMC4RHRH1HTR6 | |
| SCHEMBL8918158 | 0.60 | CA1 (0.49) | MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247559-A1 | Benzofuropyrimidinones | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | claimed |
| EP-2097419-A1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | Exelixis, Inc. (US) | 2009-09-09 | — | — | EP | claimed |
| WO-2009086264-A1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS, INC. (US) | 2009-07-09 | — | — | WO | claimed |
| EP-2097419-B1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS INC (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20090247559-A1 | Benzofuropyrimidinones | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| EP-2097419-A1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | Exelixis, Inc. (US) | 2009-09-09 | — | — | EP | disclosed |
| WO-2009086264-A1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247559-A1 | Benzofuropyrimidinones | F12, BRI3BP, BRD1 | SIGMAR1 647/4885POLB 1929/4885MC4R 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.